Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-11
2007-09-11
Nickol, Gary B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004300, C424S085100
Reexamination Certificate
active
10740098
ABSTRACT:
The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4430266 (1984-02-01), Frank
patent: 4530840 (1985-07-01), Tice et al.
patent: 4622219 (1986-11-01), Haynes
patent: 4725442 (1988-02-01), Haynes
patent: 4767628 (1988-08-01), Hutchinson
patent: 4891225 (1990-01-01), Langer et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5444047 (1995-08-01), DiPasquale
patent: 5506302 (1996-04-01), Shiono et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5654010 (1997-08-01), Johnson et al.
patent: 5656722 (1997-08-01), Dorschug
patent: 5891722 (1999-04-01), Fuks et al.
patent: 6689747 (2004-02-01), Filvaroff et al.
patent: 0 055 945 (1982-07-01), None
patent: 0 324 274 (1989-07-01), None
patent: 0 375 437 (1990-06-01), None
patent: 0 427 296 (1991-05-01), None
patent: 0 534 705 (1991-09-01), None
patent: 0 195 691 (1991-11-01), None
patent: 0 519 750 (1992-12-01), None
patent: 0 171 147 (1993-03-01), None
patent: 0 171 886 (1993-03-01), None
patent: 0 171 887 (1993-03-01), None
patent: 0 544 466 (1993-06-01), None
patent: 0 557 976 (1993-09-01), None
patent: 0 560 723 (1993-09-01), None
patent: 0 214 826 (1994-10-01), None
patent: 0 434 652 (1994-11-01), None
patent: 0 436 469 (1995-02-01), None
patent: 0 704 527 (1996-04-01), None
patent: 86/01540 (1986-03-01), None
patent: 89/10937 (1989-11-01), None
patent: 91/19510 (1991-12-01), None
patent: 92/13565 (1992-08-01), None
patent: 94/04569 (1994-03-01), None
patent: 95/07931 (1995-03-01), None
patent: 95/22614 (1995-08-01), None
patent: 96/04307 (1996-02-01), None
patent: 96/07399 (1996-03-01), None
patent: 96/20724 (1996-07-01), None
patent: 96/40072 (1996-12-01), None
patent: 97/03692 (1997-02-01), None
patent: 97/35563 (1997-10-01), None
patent: 97/39032 (1997-10-01), None
patent: 98/45427 (1998-10-01), None
patent: 99/51262 (1999-10-01), None
Amin and Abramson., “The Role of Nitric Oxide in Articular Cartilage Breakdown in Osteoarthritis.”Curr. Opin. Rheum. 10(3):263-268 (1998).
Arend W. P. et al., “Interleukin-1 Receptor Antagonist: Role in Biology”Ann. Rev. Immunol. 16:27-55.
Athanasiou et al., “Effects of diabetes mellitus on the biomechanical properties of human ankle cartilage”.Clin. Orthop. Rel. Res. 368:182-189 (1999).
Baker et al., “The structure of 2Zn pig insulin crystals at 1.5 . . . resolution”Philos. Trans. Royal Soc. London. Ser. B. Biol. Sci. 319(1195):369-456 (Jul. 6, 1988).
Balschmidt, P., “Prepn. of active (B28-Asp) -human insulin—using the lysyl specific endopeptides from Achromobacter lyticus to convert (B28-Asp) -human insulin precursor”Research Disclosure(RD 365030 (Acct. 94-308986)) pp. 487-488 (1994).
Baragi et al., “Transplantation of Adenovirally Transduced Allogenic Chondrocytes into Articular Cartilage Defects In Vivo.”Osteoarthritis and Cartilage. 5(4):275-282 (1997).
Baragi et al., “Transplantation of Transduced Chondrocytes Protects Articular Cartilage from Interleukin 1-Induced Extracellular Matrix Degradation”J. Clin. Invest. 96(5):2454-2460 (Nov. 1995).
Bell et al., “Sequence of the human insulin gene”Nature284:26-32 (Mar. 1980).
Bendele and Hulman, “Effects of body weight restriction on the development and progression of spontaneous osteoarthritis in guinea pigs”Arthritis Rheum. 34(9):1180-1184 (Sep. 1991).
Bendele and Hulman, “Spontaneous cartilage degeneration in guinea pigs”Arthritis Rheum. 31(4):561-565 (Apr. 1988).
Bentley et al., “Role of B13 Glu in Insulin Assembly: The Hexamer Structure of Recombinant Mutant (B13 Glu-Gln) Insulin”J. Mole. Biol. 228:1163-1176 (1992).
Berridge and Tan, “Characterization of the cellular reduction of 3-(4.5-dimethylthiazol-2-y)-2,5-diphenyltetrazolium bromide, etc.”Archives of Biochemistry&Biophysics303(2):474-482 (1993).
Bhakta et al., “The Insulin-like Growth Factors (IGFs) and I and II Bind to Articular Cartilage via the IGF-binding Proteins”Journal of Biological Chemistry275(8):5860-5866 (Feb. 25, 2000).
Binder, C., “A Theoretical Model for the Absorption of Soluble Insulin”Artifical Systems for Insulin Delivery, P. Brunetti et al. Eds., New York:Serono Symposia Publs. from Raven Press vol. 6:53-57 (1983).
Blundell et al., “Insulin: The structure in the crystal and its reflection, etc.” (Laboratory of Molecular Biophysics, South Parks Road, Oxform, England) pp. 279-402.
Brader et al., “Insulin hexamers: new conformations and applications”TIBS16:341-345 (Sep. 1991).
Brange and Langkjaer, “Chemical stability of insulin. 3. Influence of excipients, formulation, and pH”Acta Pharm. Nord. 4(3):149-158 (1992).
Brange and Langkjaer, “Insulin formulation and delivery”Protein Delivery: Physical Systems, Sanders and Hendren, New York:Plenum Press, Chapter 13, pp. 343-410 (1997).
Brange et al., “Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations”Pharm. Res. 9(6):715-726 (1992).
Brange et al., “Chemical Stability of Insulin. 2. Formulation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations”Pharm. Res. 9(6):727-734 (1992).
Brange et al., “Designing insulin for diabetes therapy by protein engineering”Curr. Opin. Struct. Biol. 1:934-940 (1991).
Brange et al., “Monomeric insulins and their experimental and clinical implications”Diabetes Care13(9):923-954 (Sep. 1990).
Brems et al., “Improved insulin stability through amino acid substitution”Protein Engineering5(6):519-525 (1992).
Buckwalter et al., “Restoration of Injured or Degenerated Articular Cartilage”J. Am. Acad. Orthop. Surg. 2(4):192-201 (1994).
Chance et al., “Chemical, physical, and biologic properties of biosynthetic human insulin”Diabetes Care4(2):147-154 (1981).
Chen et al., “Chondrocyte Transplantation and Experimental Treatment Options for Articular Cartilage Defects”Amer. J. Orthop. 26(6):396-406 (1997).
Chevalier and Tyler, “Production of binding proteins and role of the insulin-like growth factor I binding protein 3 in human articular cartilage explants”Brit. J. Rheum. 35:515-522 (1996).
Chin et al., “Interactions Between Interleukin-1 and Basic Fibroblast Growth Factor on Articular Chondrocytes. Effects on Cell Growth, Prostanoid Production, and Receptor Modulation”Arthritis Rheum. 34(3):314-324 (Mar. 1991).
Cleland and Jones, “Stable formulation of recombinant human growth hormone and interferon-γ for Microencapsulation in biodegradable microspheres”Pharm. Res. 13(10):1464-1475 (1996).
Cleland, J.L., “Design and production of single-immunization vaccines using polyactide polyglycolide microsphere systems”Vaccine Design: The Subunit and Adjuvant Approach, M.F. Powell and M.J. Newman, New York:Plenum Press, Chapter 18, pp. 439-462 (1995).
Cohen and Foglia, “Effect of insulin in vitro on
Filvaroff Ellen H.
Okumu Franklin W.
Genetech, Inc.
Jiang Dong
Nickol Gary B.
Svoboda Craig G.
LandOfFree
Use of insulin for the treatment of cartilaginous disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of insulin for the treatment of cartilaginous disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of insulin for the treatment of cartilaginous disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747030